Nu-Med Plus (NUMD) Amortization of Deferred Charges (2013 - 2022)

Nu-Med Plus (NUMD) posted Amortization of Deferred Charges of $3084.0 for Q1 2022, down 89.96% sequentially from $30716.0 in Q1 2014.

Nu-Med Plus (NUMD) Amortization of Deferred Charges (2013 - 2022) Analysis & Trends

Nu-Med Plus has reported Amortization of Deferred Charges for 3 years, with the latest figure at $3084.0 in Q1 2022.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $3084.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $3084.0 (changed N/A YoY) and the FY2022 annual result came in at $8222.0, changed N/A from the prior year.
Amortization of Deferred Charges fell to $3084.0 in Q1 2022 per NUMD's latest filing, from $30716.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $3084.0 in Q1 2022 and troughed at $3084.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.28 Bn	193.68 Bn	7.27 Bn
2	Stryker	129.49 Bn	126.02 Bn	4.50 Bn
3	Medtronic	119.55 Bn	110.33 Bn	6.41 Bn
4	Boston Scientific	73.67 Bn	73.13 Bn	3.85 Bn
5	Edwards Lifesciences	52.28 Bn	48.03 Bn	1.35 Bn
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn
7	GE HealthCare Technologies	34.13 Bn	32.02 Bn	2.18 Bn
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn
9	Steris	23.17 Bn	22.69 Bn	684.20 Mn
10	Nu-Med Plus	2.03 Mn	2.02 Mn	-

Download Data